AA 193
AA 193 is an orally active uricosuric agent. AA 193 inhibits the net reabsorption of uric acid in nephrons, regulates the renal reabsorption process of filtered uric acid, promotes uric acid excretion in a dose-dependent manner, and reduces serum uric acid levels. AA 193 mildly inhibits the activity of xanthine dehydrogenase (XDH). AA 193 can be used in studies related to hyperuricemia.
For research use only. We do not sell to patients.
- CAS No.: 107804-48-8
- Formula: C16H10ClNO4
- Molecular Weight:315.71
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
AA 193 (1 mM; 20 min) has no effect on uricase activity in the lysosomal fraction of rat liver homogenate[1].
AA 193 (0.2-1 mM; 20 min) shows no effect on xanthine dehydrogenase activity in the cytosolic fraction of rat liver homogenate at a concentration of 0.2 mM, while 1 mM AA-193 slightly inhibits the activity of this enzyme[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
AA-193 (20-100 mg/kg; p.o.; once daily; for 7 consecutive days) exerts dose-dependent urate-lowering activity in hyperuricemic rats[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar-Immamichi (8-week-old male, normal, fed standard diet pellet CE-2)[1]
-
Dosage:20 mg/kg; 50 mg/kg; 100 mg/kg
-
Administration:p.o.; daily; 7 days
-
Result:Increased 24-hour urate excretion by 16.9% (20 mg/kg), 24.4% (50 mg/kg), and 25.0% (100 mg/kg) compared to vehicle control after first administration.
Maintained dose-dependent uricosuric activity over 7 consecutive administrations.
Did not significantly alter plasma urate concentrations throughout the study.
Increased plasma allantoin by 11.4% in the 100 mg/kg group on day 7, while urinary and plasma allantoin levels were largely unchanged otherwise.
Increased fractional excretion of urate at 50 mg/kg, with peak responses occurring 2 hours after administration, correlating with plasma AA-193 concentrations (57.1 μg/mL at 2 hours, 21.1 μg/mL at 8 hours on day 1, undetectable by 24 hours).
Showed similar plasma AA-193 concentration time course on day 1 and day 7.
-
Animal Model:Wistar-Immamichi (8-week-old male, hyperuricemic, fed standard diet pellet CE-2 blended with 2.5% oxonate potassium salt for days 1 to 8)[1]
-
Dosage:20 mg/kg; 50 mg/kg; 100 mg/kg
-
Administration:p.o.; daily; 7 days
-
Result:Increased urate excretion rate at all doses.
Caused a dose-dependent decrease in plasma urate levels, with a significant 18.2% reduction in the 100 mg/kg group on day 7 compared to vehicle control.
Left plasma and urinary allantoin levels unchanged.
Increased fractional excretion of urate at 50 mg/kg, mirroring the relationship seen in normal rats.
Resulted in plasma urate levels and urate excretion rates 6 to 10 times higher than in normal rats, while fractional excretion of urate and inulin clearance values were comparable to normal rats.
Chemical Information
-
CAS No. 107804-48-8
-
Molecular Weight 315.71
-
Formula C16H10ClNO4
-
SMILES
O=C(C1OC2=C(C1)C3=C(C(C4=CC=CC=C4)=NO3)C=C2Cl)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
AA 193 Related Classifications
HY-106300 Related Classifications
Powered by Bioz